Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapse-remitting Multiple Sclerosis”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableUnknownNCT01250665
What this trial is testing

Study Comparing Corpus Callosum Atrophy as a Marker of Later Development of Cognitive Impairment in Patients With Multiple Sclerosis

Who this might be right for
Multiple SclerosisCognitive Impairment
Cantonal Hospital of St. Gallen 65
Large-scale testing (Phase 3)Study completedNCT00355134
What this trial is testing

Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
Novartis 1,083
Not applicableUnknownNCT06195800
What this trial is testing

Biomarkers of aHSCT

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Sheffield Teaching Hospitals NHS Foundation Trust 15
Testing effectiveness (Phase 2)Study completedNCT00168701
What this trial is testing

Efficacy and Safety of BG00012 in MS

Who this might be right for
Multiple Sclerosis
Biogen 260
Testing effectiveness (Phase 2)Study completedNCT02410200
What this trial is testing

Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Biogen 22
Large-scale testing (Phase 3)UnknownNCT02220244
What this trial is testing

Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
MedDay Pharmaceuticals SA 105
Post-approval studies (Phase 4)Enrolling By InvitationNCT06495593
What this trial is testing

Effects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple Sclerosis

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
University of California, San Francisco 5
Not applicableUnknownNCT04260711
What this trial is testing

Discontinuing Disease-modifying Therapies in Stable Relapsing - Onset Multiple Sclerosis (DOT-MS).

Who this might be right for
Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingMultiple Sclerosis, Secondary Progressive
Amsterdam UMC, location VUmc 130
Not applicableUnknownNCT05245344
What this trial is testing

Effects of Ozanimod on Immune-mediated Mechanisms of Neurodegeneration in Multiple Sclerosis - a Preclinical Study

Who this might be right for
Relapsing-Remitting Multiple Sclerosis (RRMS)Neuromyelitis OpticaHealthy
Neuromed IRCCS 154
Large-scale testing (Phase 3)Study completedNCT02744222
What this trial is testing

Comparative Clinical Trial to Evaluate Efficacy, Safety and Tolerance of BCD-054 and Avonex® for Treatment of Patients With Remitting-relapsing Multiple Sclerosis

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Biocad 399
Not applicableEnrolling By InvitationNCT06641271
What this trial is testing

Study to Investigate Vagus Nerve Stimulation Paired With Motor Task for Remyelination and Functional Recovery

Who this might be right for
Multiple Sclerosis (MS) - Relapsing-remittingMultiple Sclerosis
University of Colorado, Denver 70
Not applicableNot Yet RecruitingNCT06949956
What this trial is testing

Administration of Fingolimod in Greek Patients With Multiple Sclerosis.

Who this might be right for
Relapsing Remitting Multiple Sclerosis
Elpen Pharmaceutical Co. Inc. 140
Not applicableEnded earlyNCT02580669
What this trial is testing

Study by Magnetic Resonance Imaging in the Progressive Forms of Multiple Sclerosis

Who this might be right for
Progressive Multiple SclerosisMultiple Sclerosis, Relapsing-Remitting
University Hospital, Montpellier 70
Early research (Phase 1)Study completedNCT03551275
What this trial is testing

Dose Escalation Study of the Pharmacodynamics, Pharmacokinetics, Safety, and Immunogenicity of BCD-132 in Patients With Relapsing-Remitting Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
Biocad 24
Large-scale testing (Phase 3)Active Not RecruitingNCT03958877
What this trial is testing

Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Biogen 152
Large-scale testing (Phase 3)Active Not RecruitingNCT06700343
What this trial is testing

Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)

Who this might be right for
Relapsing-remitting Multiple Sclerosis (RRMS)
Amgen 152
Not applicableActive Not RecruitingNCT07497126
What this trial is testing

The Prevalance of Malnutrition and Its Association With Disability in Patients With Relapsing-Remitting Multiple Sclerosis

Who this might be right for
Relapsing Remitting Multiple Sclerosis (RRMS)Malnutrition or Risk of Malnutrition
Antalya Training and Research Hospital 169
Testing effectiveness (Phase 2)Study completedNCT02638038
What this trial is testing

This is a Randomized Study Comparing Two Doses of INT131 ( 3 mg and 1 mg) Administered Orally (PO) Daily (QD) Versus Placebo 1 Tablet PO QD in Subjects With Treatment-naïve RRMS for ≤ 3 Years

Who this might be right for
Multiple Sclerosis, Relapsing Remitting
InteKrin Therapeutics, Inc. 228
Testing effectiveness (Phase 2)UnknownNCT02587715
What this trial is testing

Allogeneic Human UC-MSC and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Novo Cellular Medicine Institute LLP 69
Testing effectiveness (Phase 2)WithdrawnNCT00497952
What this trial is testing

Allogeneic Stem Cell Transplantation for the Treatment of Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
Talaris Therapeutics Inc.
Next Page